Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DaKTP-Hib-HepB-Pneu vaccine
- Development stage
- Approved
- Lead developer
- Northwest Clinics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DaKTP-Hib-HepB-Pneu vaccine refers to the co-administration of a hexavalent combination vaccine (protecting against diphtheria, acellular pertussis, tetanus, poliomyelitis, Haemophilus influenzae type b, and hepatitis B) and a pneumococcal conjugate vaccine (protecting against Streptococcus pneumoniae). This immunization regimen is routinely administered to infants at 2 months of age under the Dutch National Immunisation Programme. A clinical study conducted by the Medisch Centrum Alkmaar evaluated the safety of this first routine immunization in clinically stable preterm infants born before 33 weeks of gestation after hospital discharge, demonstrating that home immunization without hospital cardiorespiratory monitoring is safe for this population.
- Brand names
- Infanrix HexaVaxelisPrevenarPrevenar 13Prevenar13Prevenar-13Synflorix
- Other names
- DaKTP-Hib-HepB-PneuDKTP-Hib-HepB-PneuDaKTP-Hib-HepB + PneuDKTP-Hib-HepB + Pneuhexavalent vaccine + pneumococcal conjugate vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)Diphtheria toxinCPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on DaKTP-Hib-HepB-Pneu vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DaKTP-Hib-HepB-Pneu vaccine.